Updates in Healthcare Maintenance and Monitoring of Children with Inflammatory Bowel Disease in the Era of Biologic Therapies

Purpose of Review As the therapeutic armamentarium for the management of pediatric inflammatory bowel disease (IBD) expands, it is increasingly challenging for pediatric gastroenterologists and pediatric primary care providers to stay abreast of the available therapies and the associated side effect...

Full description

Saved in:
Bibliographic Details
Published in:Current treatment options in pediatrics 2019-12, Vol.5 (4), p.466-482
Main Authors: Patel, Trusha, Grossman, Andrew B.
Format: Article
Language:English
Subjects:
Anemia
Antibiotics
Arthritis
Chicken pox
Critical Care Medicine
Crohns disease
Diarrhea
Drug dosages
Enzymes
Family Medicine
FDA approval
Gastroenterology
General Practice
Headaches
Health care
Infections
Inflammatory bowel disease
Intensive
Kinases
Maternal and Child Health
Medical laboratories
Medicine
Medicine & Public Health
Metabolism
Metabolites
Nausea
Pediatric Gastroenterology (SA Saeed and K Sandberg
Pediatrics
Section Editors
Steroids
Topical Collection on Pediatric Gastroenterology
Toxicity
Tuberculosis
Vaccines
Vomiting
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose of Review As the therapeutic armamentarium for the management of pediatric inflammatory bowel disease (IBD) expands, it is increasingly challenging for pediatric gastroenterologists and pediatric primary care providers to stay abreast of the available therapies and the associated side effects, required monitoring, and specific health maintenance needs for these patients. Here, we review the currently available therapies and general treatment strategies for the management of pediatric IBD, along with clinical considerations in the context of general pediatric care. Recent Findings The number of therapies for the management of IBD has grown rapidly in recent years. While pediatric providers have become adept with the use of anti-tumor necrosis factor-alpha therapies, and large safety registries have helped us understand the risks of these biologic agents, there is much left to learn about the pediatric use of newer therapies, such as vedolizumab, ustekinumab, and tofacitinib. Summary Biologic therapies and other targeted anti-inflammatory therapies are increasingly used in children with IBD. Pediatric primary care providers and pediatric gastroenterologists must be aware of the risks, benefits, and additional implications of these therapies. Vaccination strategies, recognition and management of routine or opportunistic infections, assessment of rashes, and cancer screening represent areas of particular importance in these children.
ISSN:2198-6088
2198-6088
DOI:10.1007/s40746-019-00181-4